158 related articles for article (PubMed ID: 38751886)
1. "A second birthday"? Experiences of persons with multiple sclerosis treated with autologous hematopoietic stem cell transplantation-a qualitative interview study.
Volz T; Sippel A; Fischbach F; Richter J; Willison AG; Häußler V; Heesen C
Front Neurol; 2024; 15():1384551. PubMed ID: 38751886
[TBL] [Abstract][Full Text] [Related]
2. Experiences of being treated with autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: A qualitative interview study.
Tolf A; Gauffin H; Burman J; Landtblom AM; Flensner G
PLoS One; 2024; 19(2):e0297573. PubMed ID: 38324607
[TBL] [Abstract][Full Text] [Related]
3. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
[TBL] [Abstract][Full Text] [Related]
4. Patients' expectations of autologous hematopoietic stem cell transplantation as a treatment for MS.
De Kleermaeker FGCM; Uitdehaag BMJ; van Oosten BW
Mult Scler Relat Disord; 2020 Jan; 37():101467. PubMed ID: 31678857
[TBL] [Abstract][Full Text] [Related]
5. Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline.
Bayas A; Berthele A; Blank N; Dreger P; Faissner S; Friese MA; Gerdes LA; Grauer OM; Häussler V; Heesen C; Janson D; Korporal-Kuhnke M; Kowarik M; Kröger N; Lünemann JD; Martin R; Meier U; Meuth S; Muraro P; Platten M; Schirmer L; Stürner KH; Stellmann JP; Scheid C; Bergh FT; Warnke C; Wildemann B; Ziemssen T
Ther Adv Neurol Disord; 2023; 16():17562864231180730. PubMed ID: 37780055
[TBL] [Abstract][Full Text] [Related]
6. Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation.
Marchi L; Mariottini A; Viti V; Bianchi A; Nozzoli C; Repice AM; Boncompagni R; Ginestroni A; Damato V; Barilaro A; Chiti S; Saccardi R; Fainardi E; Massacesi L
Front Neurol; 2024; 15():1373385. PubMed ID: 38899059
[TBL] [Abstract][Full Text] [Related]
7. Autologous hematopoietic stem cell transplantation of patients with aggressive relapsing-remitting multiple sclerosis: Danish nation-wide experience.
Jespersen F; Petersen SL; Andersen P; Sellebjerg F; Magyari M; Sørensen PS; Blinkenberg M
Mult Scler Relat Disord; 2023 Aug; 76():104829. PubMed ID: 37364374
[TBL] [Abstract][Full Text] [Related]
8. Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis.
Nabizadeh F; Pirahesh K; Rafiei N; Afrashteh F; Ahmadabad MA; Zabeti A; Mirmosayyeb O
Neurol Ther; 2022 Dec; 11(4):1553-1569. PubMed ID: 35902484
[TBL] [Abstract][Full Text] [Related]
9. Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series.
Nicholas RS; Rhone EE; Mariottini A; Silber E; Malik O; Singh-Curry V; Turner B; Scalfari A; Ciccarelli O; Sormani MP; Olavarria E; Mehra V; Gabriel I; Kazmi MA; Muraro P;
Neurology; 2021 Aug; 97(9):e890-e901. PubMed ID: 34253634
[TBL] [Abstract][Full Text] [Related]
10. Impact of Immunoablation and Autologous Hematopoietic Stem Cell Transplantation on Treatment Cost of Multiple Sclerosis: Real-World Nationwide Study.
Orlewska K; Bogusz K; Podlecka-Piętowska A; Nojszewska M; Markiewicz M; Liwoch R; Orlewski P; Śliwczyński A; Zakrzewska-Pniewska B; Snarski E
Value Health Reg Issues; 2021 Sep; 25():104-107. PubMed ID: 33865219
[TBL] [Abstract][Full Text] [Related]
11. Healthcare utilization and costs associated with autologous haematopoietic stem cell transplantation in Norwegian patients with relapsing remitting multiple sclerosis.
Gottschlich KN; Zolic-Karlsson Z; Aas E; Kvistad SAS; Bø L; Torkildsen Ø; Lehmann AK
Mult Scler Relat Disord; 2024 Apr; 84():105507. PubMed ID: 38412758
[TBL] [Abstract][Full Text] [Related]
12. Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing-Remitting Multiple Sclerosis Patients.
Bertolotto A; Martire S; Mirabile L; Capobianco M; De Gobbi M; Cilloni D
Neurol Ther; 2020 Dec; 9(2):197-203. PubMed ID: 32548740
[TBL] [Abstract][Full Text] [Related]
13. Intensive immunosuppression followed by autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis.
Lycke J; Lenhoff S
Ther Adv Neurol Disord; 2020; 13():1756286420929467. PubMed ID: 32636931
[TBL] [Abstract][Full Text] [Related]
14. Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis.
Kasarełło K; Snarski E; Sulejczak D; Ciesielski T; Wiśniewska A; Wrzesień R; Cudnoch-Jędrzejewska A
Arch Immunol Ther Exp (Warsz); 2021 Jun; 69(1):17. PubMed ID: 34181099
[TBL] [Abstract][Full Text] [Related]
15. Detailed immunophenotyping of the hematopoietic graft from patients with multiple sclerosis undergoing autologous hematopoietic stem cell transplant.
Massey J; Visweswaran M; Khoo M; Hendrawan K; Sutton I; Withers B; Ma D; Moore J
Cytotherapy; 2023 Dec; 25(12):1271-1276. PubMed ID: 37737765
[TBL] [Abstract][Full Text] [Related]
16. Disease modifying therapy management of multiple sclerosis after stem cell therapies: A retrospective case series.
Manzano GS; Holroyd KB; Kaplan T; Bhattacharyya S; Chitnis T; Hotan G; Zurawski J; Galetta KM; Mateen FJ
Mult Scler Relat Disord; 2022 Jul; 63():103861. PubMed ID: 35576727
[TBL] [Abstract][Full Text] [Related]
17. From "being at war" to "getting back on your feet": A qualitative study on experiences of patients with systemic sclerosis treated with hematopoietic stem cell transplantation.
Spierings J; de Bresser CJ; van Rhijn-Brouwer FC; Pieterse A; Vonk MC; Voskuyl AE; de Vries-Bouwstra JK; van Laar JM; Kars MC
J Scleroderma Relat Disord; 2020 Oct; 5(3):202-209. PubMed ID: 35382525
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive Therapy After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients-High Efficacy of Rituximab.
Gernert M; Tony HP; Fröhlich M; Schwaneck EC; Schmalzing M
Front Immunol; 2021; 12():817893. PubMed ID: 35111167
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of Inflammatory and Neurodegenerative Biomarkers after Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
Ruder J; Dinner G; Maceski A; Berenjeno-Correa E; Müller AM; Jelcic I; Kuhle J; Martin R
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142860
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma.
Lemieux C; Ahmad I; Bambace NM; Bernard L; Cohen S; Delisle JS; Fleury I; Kiss T; Mollica L; Roy DC; Sauvageau G; Roy J; Lachance S
Biol Blood Marrow Transplant; 2020 Jan; 26(1):157-161. PubMed ID: 31521818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
